TKNO
Alpha Teknova, Inc. Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$7.36Close
$394.2MMarket cap
$5.85 – $9.3352-week range
Nov 4, 2026Next report · after the close
Highlights
Cautions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
21%
1wk
up 14.6%
price change
1mo
down 17.3%
price change
12-month return
0%
total, dividends included
F-score
5 / 9
Mixed
Altman Z
5.12
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.7×
price / book
Earnings yield
down 4.2%
EBIT / enterprise value
Cheaper than
21%
of the market · expensive
Revenue growth
up 7%
year on year
EPS growth
—
latest quarter
Sales growth
up 18%
latest quarter · +5 pts
ROE
down 23%
return on equity
Free cash margin
down 24%
-$9.8M FCF
D/E
0.19
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- issued more shares
- profitability improving
- profits backed by cash
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Gross margin 19.2% → 33.2%
Trade setup
ATR%
9.1%
$0.67 a day · 2×ATR $6.02
RS
—
vs the universe
Trend
—
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
0.97
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
Last reported
Oct 21, 2026
Last shock
Oct 21, 2026-21% in one session14.5× volumeon results+26% since
Financials
- Gross 33%
- Net -43%
- Free cash -24%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $31.3M | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M |
| Gross margin | 57% | 48% | 42% | 28% | 19% | 33% |
| Operating income | $4.7M | -$12.0M | -$49.7M | -$35.6M | -$26.1M | -$17.0M |
| Net income | $3.6M | -$9.8M | -$47.5M | -$36.8M | -$26.7M | -$17.3M |
| Net margin | 11% | -27% | -115% | -100% | -71% | -43% |
| Earnings per share | $0.94 | -$0.61 | -$1.69 | -$1.16 | -$0.57 | -$0.32 |
| Free cash flow | -$3.0M | -$28.9M | -$55.5M | -$26.7M | -$13.5M | -$9.8M |
| Free cash margin | -9% | -78% | -134% | -73% | -36% | -24% |
| Cash | $3.3M | $87.5M | $42.2M | $28.5M | $3.7M | $5.9M |
| Long-term debt | $0 | $11.9M | $22.0M | $13.3M | $9.4M | $13.1M |
| Shareholders' equity | $16.8M | $143.2M | $99.9M | $90.0M | $82.4M | $68.8M |
| Shares outstanding | 3.60m | 28.01m | 28.18m | 40.79m | 53.41m | 53.56m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 7, 2025 | Annual ↗ | Dec 31, 2024 | 66d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 27, 2024 | Annual ↗ | Dec 31, 2023 | 87d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 21, 2026 | Material agreement · Results · Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| Jun 1, 2026 | Director or officer change · Shareholder vote ↗ |
| May 6, 2026 | Results · Item 5.05 ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 23, 2025 | Shareholder vote ↗ |
| May 8, 2025 | Results ↗ |
| Mar 4, 2025 | Material agreement · Results ↗ |
| Nov 7, 2024 | Results ↗ |
| Aug 13, 2024 | Results ↗ |